Priya Shinde

What Are The Major Driving Factors Of Cold Plasma Market?   The Cold Plasma Market is primarily driven by the unique benefits of cold plasma techniques, demand for innovative production techniques within the textile industry and other end-use industries, and soaring concerns of safety and decontamination for processed foods.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187065928   Cold plasma technology has immense potential across a broad range of application areas, including plastic & polymer, textiles, electronics, food & agriculture, and medicine. Compared to its alternatives, it boasts several unique benefits, including an environment-friendly nature.   Industry Overview The global cold plasma market size is projected to reach USD 3.3 billion by 2026 from USD 1.6 billion in 2021, at a CAGR of 15.0% during the forecast period. The increasing prevalence of food-borne diseases, increasing use of cold plasma in wound healing and cancer treatment, innovation in textile production, and the benefits of cold plasma in all industrial areas are the major factors driving the growth of this market.   Market Segmentation   Cold Plasma Market by Industry (Textile, Electronics & Semiconductors, Polymers & Plastic, Food & Agriculture, Medical, Others), Application (Adhesion, Printing, Wound Healing), Regime (Atmospheric, Low Pressure) - Global Forecast to 2026. Cold plasma technology has immense potential across a broad range of application areas, including plastic & polymer, textiles, electronics, food & agriculture, and medicine.   Players in the global cold plasma industry such as Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH, (Germany), Henniker Plasma (UK), Enercon Industries (US), AcXys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), terraplasma GmbH (Germany), Molecular Plasma Group (Germany), CINOGY GmbH (Germany), and US Medical Innovations (US) Nordson Corporation held the leading position in the cold plasma market. The company has a highly diversified product portfolio, which includes a wide range of cold plasma products. Nordson’s position in the market can be attributed to its active R&D activities and wide global distribution footprint. Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=187065928 This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies. About MarketsandMarkets™  MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cold-plasma-market.asp Visit Our Web Site: https://www.marketsandmarkets.com Content Source:  https://www.marketsandmarkets.com/PressReleases/cold-plasma.asp

Who are the key players in the Glycomics/Glycobiology Market? Glycomics Market research report forecast 2022-2027 has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the industry. Buyers of the report will have access to accurate Porter’s 5 Analysis, PESTLE, SWOT, and other types of analysis on the global Glycobiology market. The report aims to provide a thorough and accurate analysis of the industry, taking into account forecast, competitive intelligence, technical risks, innovations, and other pertinent data. Readers will learn about significant opportunities in the worldwide market, as well as major factors driving and inhibiting growth. To Understand Business Strategies, Request For a Sample PDF Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525 The glycomics/glycobiology market is expected to grow at a CAGR of 15.5% during the forecast period. The growth of the market is due to emerging use of glycans as biomarker, increased prevalence of cancer, advancing technology for glycan analysis, collaborations and partnerships among market players for the development of glycobiology products. The Prominent players covered in the Glycomics Market are: Key players in the glycomics/glycobiology market are Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA (Germany), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, (Japan), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. (Japan), Bruker Corporation (US), Shimadzu Corporation (Japan), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag (France), Kode Biotech Limited (New Zealand), Glyxera GmBH (Germany), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group (Italy), Asparia Glycomics (Spain) and Ray Biotech Life Inc. (US). Drivers: Emergence of glycans as biomarkers Glycans play a vital role in biology; alterations in glycans can lead to dangerous consequences, such as congenital disorders, heart diseases, growth defects, and epilepsy. Research has shown that mutation in glycosyltransferases or related enzymes modifies/alters the glycome and can cause over 100 types of human congenital disorders of glycosylation. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525 Recent Developments Bruker Corporation (US) acquired the IonSense (US) for expansion of the use of DART Mass spectrometers. GlycoNet (Canada) and BridgeBio Pharma Inc, (US) entered into partnership for developing medicines for treating genetic diseases through glycobiology research. North America is the fastest-growing region of the glycomics/glycobiology market in 2022. North America is estimated to be the fastest-growing segment of the market. The growth of the glycomics/glycobiology market in this region is driven by the presence of prominent market players offering glycomics products, increasing focus on glycomics research and its application in drug development and availability of research infrastructure in the US. Avail 10% Discount on various license types on Immediate Purchase @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132685525 Table of Contents: Glycomics Market Scenario 2023 Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Glycomics market. Chapter 2: Exclusive Summary – the basic information of the Glycomics Market. Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Glycomics. Chapter 4: Presenting the Glycomics Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, Patent/Trademark Analysis. Chapter 5: Displaying the by Type, End User and Region/Country 2022 – 2027 Chapter 6: Evaluating the leading manufacturers of the Glycomics market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2022-2027) Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source This Glycomics Market Research/Analysis Report Contains Answers to your following Questions: Who are the key players in the glycomics/glycobiology market? Which product segment dominates the glycomics/glycobiology market? Which application segment dominates the glycomics/glycobiology market? Which end user segment dominates the glycomics/glycobiology market? What is the market size for the glycomics/glycobiology market? Available Customizations With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:</P> An additional five company profiles

 Microbiome Diagnostics market in terms of revenue was estimated to be worth $146 million in 2023 and is poised to reach $300 million by 2028, growing at a CAGR of 15.5% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The microbiome diagnostics market is driven by a rise in the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132581140 Microbiome Diagnostics Market Scope: Report Coverage Details Market Revenue in 2023 $146 million Estimated Value by 2028 $300 million Growth Rate Poised to grow at a CAGR of 15.5% Market Size Available for 2022–2028 Forecast Period 2023–2028 Forecast Units Value (USD Million) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered Product, Technology, Sample, Application, End User, and Region Geographies Covered North America, Europe, Asia Pacific, Rest of the World Report Highlights Updated financial information / product portfolio of players Key Market Opportunity Increased collaboration of key players and small innovative companies to work on new microbiome technologies Key Market Driver Collaborative efforts between the microbiome industry and academia for microbiome research The incidence of chronic diseases across the globe has increased significantly. Microbiomes have major applications in the diagnosis of several chronic conditions, such as obesity and diabetes, and thus the prevalence of these conditions is expected to drive the demand for microbiome diagnostic products in the coming years. For instance, Globally, the number of patients suffering from diabetes is expected to grow from ∼537 million in 2021 to almost 783 million by 2045. (Source: International Diabetes Federation). Based on products, the microbiome diagnostics market is segmented into reagents & kits and instruments. Reagents & kits accounted for the largest share of the market in 2022. The large share of this product segment can primarily be attributed to repeat purchases and consumption of reagents & kits for diagnostic procedures as compared to the instruments, which have a longer shelf time and can be used for multiple procedures. The microbiome diagnostics market is segmented based on technology into 16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technologies. 16s rRNA accounted for the largest share of the microbiome diagnostics market in 2022. The high accuracy and affordability offered by 16S rRNA sequencing, and the growing number of microbiomic research activities to identify and classify various bacterial strains are driving the growth of the segment. Based on samples, the microbiome diagnostics market is segmented into fecal, saliva, skin and other samples. In 2022, feces accounted for the largest share of the microbiome-based diagnostics market. This segment is also projected to register the highest CAGR during the forecast period, owing to the rising prevalence of disease and increasing microbiome research activities. Based on applications, the microbiome diagnostics market is segmented into research applications, disease diagnostic applications. In 2022, the disease diagnostic application segment accounted for the largest share of the microbiome-based diagnostics market. The large share of this segment is due to the increasing prevalence of diseases, the increasing collaboration of industrial players and academic institutes to develop microbiome diagnostics. Based on end users, the microbiome diagnostics market is segmented into hospitals, research institutes, pharmaceutical & biotechnology companies and other end users. Hospitals accounted for largest share of the microbiome diagnostics market in 2022. The significant share of the segment is primarily due to the rising prevalence of diseases. The microbiome diagnostics market is segmented into four major regions: North America, Europe, the Asia Pacific, and Rest. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, owing to the demand for better healthcare services, and the rising prevalence of chronic. Buy an Microbiome Diagnostics Industry Report (185 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=132581140 Microbiome Diagnostics market major players covered in the report, such as: DNA Genotek (Canada) Invivo Healthcare (UK) Microba Life Sciences (US) Genetic Analysis AS (Norway) Metabiomics (US) Teraomics (US) Becton, Dickinson and Company (US) BioMe Oxford Ltd (UK) Viennalab Diagnostics (Austria) Viome Life Sciences, Inc. (US) Luxia Scientific (France) DayTwo (US) Sun Genomics (US) Atlas Biomed (UK) Quantbiome, Inc. (US) GoodGut  (US) Micronoma (US) FlightPath Biosciences (US) Microbiome Research Pvt.Ltd. (India) and Among Others Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132581140 This report categorizes the microbiome diagnostics market into the following segments and subsegments: By Product Reagents & Kits Instruments By Technology 16S rRNA Sequencing Shot Gun Metagenomics Metatranscriptomics Other Technology By Sample Faces Saliva Skin Other Sample By Application Disease Diagnostics Application Gastrointestinal Disorders Metabolic Diseases Other Application Research Application By End User Hospitals Academic and Research Institutes Biotechnology and Pharmaceutical Companies By Region North America US Canada Europe Germany UK France Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific Rest of the World Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132581140 Key Market Stakeholders: Manufacturers and distributors of microbiome-based diagnostics products Pharmaceutical and Biotechnology Companies R & D centers Diagnostic laboratories Hospitals and clinics Academic institutes Research institutes Market research and consulting firms Report Objectives: To define, describe, segment, and forecast the global microbiome diagnostics market by product, sample, application, end user and region. To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, challenges, and trends) To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall microbiome diagnostics market To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2 To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Radiation Dose Management Industry Overview The Radiation Dose Management market is projected to reach USD 422.65 million by 2025, from USD 220.22 million in 2020, at a CAGR of 13.9%. The growth of the market is driven mainly by the increasing use of medical imaging technology owing to the increasing incidence of chronic diseases, increasing concerns about radiation dose exposure, increasing installed base of radiation equipment and increasing awareness of radiation dose management. Gather more insights about the market drivers, restrains and growth of the Global Radiation Dose Management Market Radiation Dose Management Segmentation MarketsandMarkets has segmented the Radiation Dose Management market on the basis of application, end user, and region: Radiation dose management solutions accounted for the larger share of the radiation dose management market On the basis of product & service, the radiation dose management market is segmented into radiation dose management solutions and radiation dose management services. the radiation dose management solutions segment accounted for the larger share of the radiation dose management market. By application, the oncology segment accounted for the largest market share Based on application, the radiation dose management market is segmented into oncology, cardiology, orthopaedic application and other application. The oncology segment accounted for the largest market share Hospitals are the largest end users of the radiation dose management market Based on end users, the radiation dose management market is segmented into hospitals, ambulatory care settings, and other end users. The hospitals segment accounted for the largest market share Radiation Dose Management Market Regional Outlook North America Europe Asia Pacific Latin America MEA COVID -19 IMPACT ON THE RADIATION DOSE MANAGEMENT MARKET Several countries across the globe have seen non-urgent diagnostic imaging surgeries being postponed due to the pandemic. These procedures utilize additional resources and increase the risk of complications; depending on the procedure, they also increase the chance of needing equipment, resources, or materials such as hospital beds and PPE. Market Share Insights Sectra AB launched Sectra Dosetrack. Sectra AB launched Gadolinium Tracking in its dose monitoring solution. DOSE, Qaelum's dose management solution, expanded its reach in radiology and medical imaging departments in the UK. Key Companies Profile The industry is marked by the presence of various large- and small-scale businesses operators. The market is highly competitive and dominated by key participants that focus on executing innovative strategies like mergers and acquisitions, market penetration, partnerships, and distribution agreements to increase their revenue. Some prominent players in the global Drug Screening market include, Bayer AG (Germany), GE Healthcare (US), Philips Healthcare (Netherland), and Sectra AB (Sweden) Order a free sample PDF of the Radiation Dose Management Market Intelligence Study, published by MarketsandMarkets

Antibody Therapeutics Market in terms of revenue was estimated to be worth $247.3 billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a new report by MarketsandMarkets. The growing advancements in antibody engineering, the growing demand for oncology antibody therapeutics and the increasing clinical pipeline focus on antibody therapeutics are the factors supporting the growth of this market.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178852478   Browse in-depth TOC on "Antibody Therapeutics Market" 313 - Tables 51 - Figures 306 – Pages The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges. Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=178852478 Key Market Players of Antibody Therapeutics Industry: The market for antibody therapeutics market is consolidated, with key players strategizing to capture the market. Prominent players in the antibody therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others. Antibody Therapeutics Market Dynamics: Drivers: 1.  Growing advancements in antibody engineering Restraints: 1.  Stringent regulatory approval process Opportunities: 1.  Increasing collaboration of pharmaceutical companies with CROs, CDMOs and academic institutions Challenge: Complexities in manufacturing processes All the market segments have been divided for the Antibody Therapeutics market to forecast revenue and analyze trends in each of the following submarkets: By Format Monoclonal antibody Polyclonal antibody therapy Bispecific antibody Antibody fragment Other antibody formats By Disease Areas Autoimmune & inflammatory diseases Oncology Hematology Infectious diseases Osteology Immunology Neurology Other disease areas By Route of Administration Intravenous Subcutaneous Other routes of administration By Source Human Humanized Chimeric Other sources By End User Hospitals Long-term care facilities Other end users By Region North America Europe Asia Pacific (APAC) Latin America Middle East Recent Developments of Antibody Therapeutics Industry In October 2023, F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a novel TL1A directed antibody. In January 2023, AbbVie Inc. and Immunome, Inc. entered into strategic collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine. Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=178852478 About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected]

Cystatin C Assay Market in terms of revenue was estimated to be worth $377 million in 2023 and is poised to reach $540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186075328 The Cystitis C test industry is balanced for critical development within the close future, driven by a rising request for exact and dependable biomarkers in healthcare. Cystitis C, a promising marker of kidney work, is picking up noticeable quality as an elective to conventional creatinine-based estimations. With a maturing populace, the expanding predominance of incessant kidney infections, and a developing accentuation on early illness discovery, the Cystitis C measure industry is anticipated to grow quickly. Browse in-depth TOC on "Cystatin C Assay Market" 215 - Tables 42 - Figures 271 – Pages Key Market Players of Cystatin C Assay Industry: The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited. (Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria) Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186075328 Cystatin C Assay Market Dynamics: Drivers: Rising prevalence of kidney diseases Growing geriatric population Recent advancements in chemiluminescence immunoassay technologies Growth in biotechnology and biopharmaceutical industries Increasing adoption of POC testing Supportive government policies Restraints: Stringent requirements for approval of cystatin C assay instruments and consumables High development costs of cystatin C assays Opportunities: Growth opportunities in emerging economies Importance of companion diagnostics Development of condition-specific biomarkers and tests Challenge: Dearth of skilled professionals Segmentation by product and service Analyzers Kits Reagents Segmentation by application Diagnostics Research Segmentation by end user Hospitals Clinical Laboratories Pharmaceutical and Biotechnology Companies & CROs & Academic research institutes Regional segmentation North America holds largest share Asia Pacific fastest growing region Europe second largest segment Latin America and Middle East & Africa emerging markets Regional market breakdown North America largest share due to high healthcare spending, developed infrastructure Asia Pacific fastest growth from increasing healthcare access and aging populations Europe also major market but growing at slower pace than APAC Latin America and Middle East & Africa smaller markets but seeing growth Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=186075328 About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected]

HLA Typing for Transplant Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing transplants volume worldwide, rising number of transplant & diagnostic centers, technological advancements, government initiatives to boost HLA typing services, rising public -private investments boost research in HLA genotyping, and increased focus of players to enhance their manufacturing & distribution capabilities across emerging countries are likely to support the growth of HLA typing for transplant market during the forecast period. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742 In the near future, HLA typing is poised to revolutionize the transplant industry. Rapid advancements in genomics and precision medicine will enable transplant professionals to intricately match donor and recipient HLA profiles, significantly reducing the risk of rejection and the need for immunosuppressive drugs. This breakthrough technology will expand the pool of potential donors, improve transplant success rates, and usher in a new era of life-saving organ and tissue transplantation, offering hope to countless patients awaiting these life-changing procedures. Key Market Players of HLA Typing for Transplant Industry: Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US),  Luminex Corporation (US), TBG Diagnostics Limited. (Australia) FUJIREBIO (Japan),Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US). Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742 HLA Typing for Transplant Market Dynamics: Drivers: Increasing number of transplant procedures globally Restraints: costs of molecular tests used for HLA typing procedures Opportunities: Technological shift from non-molecular serological assays to gene-based HLA profiling Challenge: Significant gap between organ availability and demand   This research report categorizes the HLA typing for transplant market to forecast revenue and analyze trends in each of the following submarkets: By Product & Service Reagents & Consumables Instruments Software & Services By Technology Molecular Assay Technologies PCR-Based Molecular Assays Real-time PCR Sequence-specific Primer-PCR Sequence-specific Oligonucleotide-PCR Other PCR-based Molecular Assays Sequencing-based Molecular Assays Sanger Sequencing Next-generation Sequencing Other Sequencing-based Molecular Assays Non-molecular Assay Technologies By Application Diagnostic Applications Antibody Screening Chimerism Monitoring Others Research Applications By Transplant Type Solid Organ Transplant Soft Tissue Transplant By End User Independent Reference Laboratories Hospitals & Transplant Centers Research Laboratories & Academic Institutes By Region North America Europe Asia Pacific Latin America Middle-East Africa Recent Developments: In September 2023, Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform. Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742 About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected]